SG Americas Securities Boosts Krystal Biotech Stake by 470%

Institutional investor increases position in biotech firm focused on rare skin disorders

Apr. 2, 2026 at 9:03am

Got story updates? Submit your updates here. ›

SG Americas Securities LLC significantly increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by purchasing an additional 15,591 shares in the fourth quarter of 2025, representing a 469.9% jump in its position. The institutional investor now owns 18,909 shares of the company's stock, valued at approximately $4.66 million.

Why it matters

Krystal Biotech is a clinical-stage biotech firm developing gene therapies for rare dermatological diseases, with its lead candidate KB103 targeting dystrophic epidermolysis bullosa (DEB), a severe and debilitating blistering condition. The increased investment by SG Americas Securities suggests growing institutional confidence in the company's pipeline and future prospects.

The details

According to a recent 13F filing with the SEC, SG Americas Securities LLC raised its position in Krystal Biotech during the fourth quarter of 2025. The firm purchased an additional 15,591 shares, bringing its total ownership to 18,909 shares, or approximately 0.07% of the company's outstanding stock.

  • SG Americas Securities increased its Krystal Biotech stake in the fourth quarter of 2025.
  • The 13F filing disclosing the increased position was submitted on April 2, 2026.

The players

SG Americas Securities LLC

An institutional investor and subsidiary of Société Générale, a major French multinational investment bank and financial services company.

Krystal Biotech, Inc.

A clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases, including its lead candidate KB103 for dystrophic epidermolysis bullosa.

Got photos? Submit your photos here. ›

The takeaway

The significant increase in SG Americas Securities' stake in Krystal Biotech suggests growing institutional confidence in the company's ability to advance its pipeline of gene therapies for rare skin disorders, particularly its lead candidate KB103 for the treatment of dystrophic epidermolysis bullosa.